INNT
TOTAL INVALIDATION PROCESSED BY THE IB
03/19/2026
Back to search
Official data from USPTO
TOLERO PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
TOLERO PHARMACEUTICALS
ST13
US500000079212382Class
5, 44
Filing
79212382
Registration
5505386
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
40
Latest update
03/20/2026
Trademark type
Word
Nice classes
5, 44
Filing date
03/22/2017
Registration date
07/03/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/17/2025
Last transaction
03/20/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
Osaka 541-0045, JP
Examiner
FOSDICK, GEOFFREY A
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Sumitomo Dainippon Pharma Co., Ltd.
Representatives
Howard N. Aronson Lackenbach Siegel LLP
Technical classification
Nice Classes
Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationsanti-inflammatories; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the central nervous systemdiseases of the brainmovementocular motility and spinal cord diseasesencephalitisepilepsyAlzheimer'scerebral palsy and Parkinson's disease and central nervous systems infections; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the peripheral nervous systemamyotrophic lateral sclerosisnumbnesslightheadednessdysuria and dyshidrosis; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the urogenital systemurological diseasesinfertilitysexually transmitted diseases and inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the cardiovascular system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the endocrine systemgrowth and thyroid disorders; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the metabolic systemdiabeteshypoglycemiagoutosteoarthritismuscular dystrophyanemiabulimia nervosaanorexiaobesity and hypothyroidism; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the renal system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the gastroenterological system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the ophthalmologic system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the dermatologic systemdermatitiseczemapsoriasisskin pigmentation diseases and sexually transmitted diseases; pharmaceutical preparations for the prevention and treatment of hematologic and oncologic disorders and diseases; pharmaceutical preparations for the prevention and treatment of psychiatric disorders and diseasesanxiety disordersmood disordersschizophreniacognitive and bipolar disordersepilepsyParkinson's diseaseAlzheimer's diseasecerebral palsymultiple sclerosis and seizures; pharmaceutical preparations for the prevention and treatment of allergic disorders and diseases and disorders and diseases of the immune systemautoimmune diseases and immunologic deficiency syndromes; pharmaceutical preparations for the prevention and treatment of connective tissue and jointsconnective tissue diseasesbone diseasesspinal diseasesback painfractures and cartilage injuries; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for use in chemotherapy
Class 44
Providing medical information
Publications
History of USPTO decisions and trademark events.
40 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
02/28/2026
INPC
INVALIDATION PROCESSED
02/28/2026
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
09/17/2025
C71T
CANCELLED SECTION 71
01/17/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/03/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/26/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/04/2018
FIMP
FINAL DISPOSITION PROCESSED
10/04/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/03/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
07/03/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/17/2018
PUBO
PUBLISHED FOR OPPOSITION
04/17/2018
GPNX
NOTIFICATION PROCESSED BY IB
04/13/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/28/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/28/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/28/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/15/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/14/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/13/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/13/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/22/2017
GNRT
NON-FINAL ACTION E-MAILED
12/22/2017
CNRT
NON-FINAL ACTION WRITTEN
12/22/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/19/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/19/2017
ALIE
ASSIGNED TO LIE
12/15/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/07/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/08/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/08/2017
RFNT
REFUSAL PROCESSED BY IB
08/12/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/27/2017
RFRR
REFUSAL PROCESSED BY MPU
07/27/2017
MAFR
APPLICATION FILING RECEIPT MAILED
07/25/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/21/2017
CNRT
NON-FINAL ACTION WRITTEN
07/20/2017
DOCK
ASSIGNED TO EXAMINER
07/19/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/19/2017
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
07/14/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/13/2017
Continuous trademark protection
Get notified about every new filing that threatens TOLERO PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.